NEWS: Cohn & Wolfe chosen for Flixotide
By JOHN-PIERRE JOYCE, PR Week UK, 07 June 1996, 12:00am
Cohn and Wolfe has scooped the estimated pounds 200,000 fee account from Glaxo Wellcome subsidiary Allen and Hanburys to promote its asthma drug Flixotide.
Share this story
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.





